Tyler Crowe

One thing that's hard to shake when looking at the industry right now is FDA approvals.

The rules and processes for getting approvals look pretty different in this current administration than in prior ones.

I think we mentioned it on a prior show earlier this year, Moderna CEO Stefan Bounce said that it is scaling back clinical trials for its mRNA vaccines because it would be, as his quote said, difficult to see return on investment.

Now, that was specifically tied to

mRNA vaccines.

And we know that the current administration's position on vaccines is very different than what we've had in the past.

And I know that both of you have some ties to the healthcare industry through your families and stuff like that.

But as you look at this space as investors, have the recent changes in FDA approvals maybe changed the way you think about investing in clinical stage companies, at least in the time being?

After the break, we're going to dip into the mailbag.

Quick reminder, we want to make you part of the conversation.

If you have a stock or investing question for Matt, Lou, myself, or anyone else on The Motley Fool Money Show, you can now email us at podcasts at fool.com.

We'd love to have your mailbag segments whenever possible, so send in your questions and just remember to keep them foolish.

That email, again, is podcasts at fool.com, podcasts at fool.com.

I'm going to read this listener question that we got a little while ago.

It comes from Vijay Kant.

I apologize if I mispronounce any names.

It's a

guarantee it's going to happen whenever we do these mailbag sections.

His question was, I want to get your perspective on the long-term investment thesis of Whirlpool.

The ticker is WHR.